Moderna, Inc.

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

This company made headlines with its coronavirus vaccine.

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%

Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.

Should Leadership Hire Require Action From Everest Medicines (SEHK:1952) Investors?

Everest Medicines recently appointed Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, to lead global mRNA therapeutic development and align U.S. and China research teams. The hire brings direct experience from Moderna and other major biopharma groups in mRNA cancer vaccines and translational immuno-oncology, which could influence how Everest Medicines executes on its proprietary mRNA platform and broader pipeline. We will now assess how Everest Medicines'...

Moderna: Sell The Cancer Vaccine Hype

Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know

A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midterm election outcomes could reverse recent federal spending cuts.

How Investors Are Reacting To Merck (MRK) Phase 3 Melanoma Results

Merck & Co., Inc. is preparing to present Phase 3 melanoma data for its personalized cancer treatment with Moderna, alongside progress in its KRAS inhibitor program, including MK-1084, which previously received Breakthrough Therapy Designation for first line advanced NSCLC with KRAS G12C mutations. The combination of late stage melanoma data with Keytruda and an advancing KRAS pipeline highlights how Merck is trying to broaden its oncology revenue base beyond any single product. We will now...

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

What's Going On With Moderna Stock Monday?

Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.